LifeVantage Non-GAAP EPS of $0.05 misses by $0.01, revenue of $37.1M misses by $3.39M (LFVN:NASDAQ)
LifeVantage reported Q1 Non-GAAP EPS of $0.05, missing estimates by $0.01, and revenue of $37.1M, missing by $3.39M. Revenue declined 22.1% year-over-year. Adjusted EBITDA fell to $1.9M from $3.9M a year ago. The company plans $3M-$3.5M in capex for FY 2027 but withheld formal guidance due to a CEO transition.
How this was made
The 30-second read
Why it matters
The earnings shortfall may prompt sell‑side analysts to downgrade the stock, increasing short‑term volatility.
Market read
Earnings miss for a small‑cap could drive short‑term price pressure but limited broader market relevance.
What to watch
CEO transition and upcoming FY 2027 capex guidance could provide longer‑term upside if execution improves.
Background
LifeVantage is a micro‑cap listed on NASDAQ that provides nutraceutical products. The company is undergoing a CEO transition and has outlined modest FY 2027 capex.
Ticker impact
LifeVantage reported Q1 non‑GAAP EPS of $0.05, missing expectations by $0.01 and revenue of $37.1M, down 22.1% YoY.
likely pressure as the market prices in the earnings miss
Both EPS and revenue fell short of expectations, and adjusted EBITDA dropped sharply, suggesting weaker operating performance.
Market effects
The health‑and‑wellness supplement sector may see modest scrutiny as a micro‑cap earnings miss.
Limited to U.S. small‑cap investors; no broader regional effect.
Minimal global impact given the company's size.
Counterpoint
If the miss is already priced in, the stock could rebound on a short‑cover rally.
Key entities
- companyLifeVantage Corporation
NASDAQ‑listed nutraceutical firm reporting Q1 2026 results.
